Integrating clinical, community, and policy perspectives on human papillomavirus vaccination.
Fernández, María E; Allen, Jennifer D; Mistry, Ritesh; Kahn, Jessica A.
Annu Rev Public Health
; 31: 235-52, 2010.
Artigo em Inglês | MEDLINE | ID: mdl-20001821
Long-term study of a quadrivalent human papillomavirus vaccine.
Cell-mediated immune response: a clinical review of the therapeutic potential of human papillomavirus vaccination.
Indications and efficacy of the human papillomavirus vaccine.
HPV-type-specific response of cervical cancer cells to cisplatin after silencing replication licensing factor MCM4.
Griffithsin and Carrageenan Combination To Target Herpes Simplex Virus 2 and Human Papillomavirus.
GTL001, A Therapeutic Vaccine for Women Infected with Human Papillomavirus 16 or 18 and Normal Cervical Cytology: Results of a Phase I Clinical Trial.
Development and evaluation of multiplexed immunoassay for detection of antibodies to HPV vaccine types.
Juglone Inhibits Proliferation of HPV-Positive Cervical Cancer Cells Specifically.
Immunotherapy Targeting HPV16/18 Generates Potent Immune Responses in HPV-Associated Head and Neck Cancer.
Baseline demographic characteristics of subjects enrolled in international quadrivalent HPV (types 6/11/16/18) vaccine clinical trials.